Dupilumab for the treatment of atopic dermatitis in an austrian cohort-real-life data shows rosacea-like folliculitis

29Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.

Abstract

Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a real-life clinical setting. Effectiveness and safety outcomes were collected at baseline and after 2, 6, 10, 24, 39, and 52 weeks by using clinical scores for disease activity, as well as serological markers. Ninety-four patients from five dermatological hospitals were included. After 24 weeks of treatment, the median Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI) showed a significant reduction compared to baseline (3.9 ± 0.7 vs. 1.4 ± 0.8 and 26.5 ± 12.5 vs. 6.4 ± 6.5). Interestingly, we observed rosacea-like folliculitis as an unexpected side effect in 6.4% of patients. Dupilumab proves to be an effective and well-tolerated treatment under real-life conditions. The occurrence of rosacea-like folliculitis warrants further mechanistic investigation.

Cite

CITATION STYLE

APA

Quint, T., Brunner, P. M., Sinz, C., Steiner, I., Ristl, R., Vigl, K., … Bangert, C. (2020). Dupilumab for the treatment of atopic dermatitis in an austrian cohort-real-life data shows rosacea-like folliculitis. Journal of Clinical Medicine, 9(4). https://doi.org/10.3390/jcm9041241

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free